{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:00:47Z","timestamp":1778752847248,"version":"3.51.4"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejca.2020.09.014","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T17:56:16Z","timestamp":1600797376000},"page":"40-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Repurposing anticancer drugs for the management of COVID-19"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8414-4145","authenticated-orcid":false,"given":"Khalid","family":"El Bairi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Petrillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Le Page","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanaa","family":"Zbakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhizlane","family":"Belbaraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Said","family":"Afqir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.09.014_bib1","article-title":"Prevention and treatment of cryptosporidiosis in immunocompromised patients","volume":"1","author":"Abubakar","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2020.09.014_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.09.014_bib3","first-page":"119-132","article-title":"Ruxolitinib. Recent Results","volume":"212","author":"Ajayi","year":"2018","journal-title":"Canc Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib4","first-page":"CD008891","article-title":"Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia","volume":"2016","author":"Alazzam","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2020.09.014_bib5","doi-asserted-by":"crossref","first-page":"253-264","DOI":"10.2147\/DDDT.S94165","article-title":"Plitidepsin: design, development, and potential place in therapy","volume":"11","author":"Alonso-\u00c1lvarez","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"13","key":"10.1016\/j.ejca.2020.09.014_bib6","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2165\/00003495-200767130-00015","article-title":"Nitazoxanide: a review of its use in the treatment of gastrointestinal infections","volume":"67","author":"Anderson","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jac\/dkv363","article-title":"Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1","volume":"71","author":"Badia","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib9","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.xphs.2018.09.010","article-title":"Drug repurposing for Ebola virus disease: principles of consideration and the animal rule","volume":"108","author":"Bai","year":"2019","journal-title":"J Pharmaceut Sci"},{"issue":"8","key":"10.1016\/j.ejca.2020.09.014_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184107","article-title":"Nitazoxanide is active against Mycobacterium leprae","volume":"12","author":"Bailey","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2020.09.014_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7935475","article-title":"Results of a randomized, double-blinded, placebo-controlled, phase 2.5 study of saracatinib (AZD0530), in patients with recurrent osteosarcoma localized to the lung","volume":"2020","author":"Baird","year":"2020","journal-title":"Sarcoma"},{"key":"10.1016\/j.ejca.2020.09.014_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019","author":"Barlow","year":"2020","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib13","doi-asserted-by":"crossref","first-page":"65-70","DOI":"10.1007\/s11934-013-0312-2","article-title":"Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer","volume":"14","author":"Barlow","year":"2013","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.014_bib14","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200652","article-title":"Targeting potential drivers of COVID-19: neutrophil extracellular traps","volume":"217","author":"Barnes","year":"2020","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/cvr\/cvq105","article-title":"Vascular endothelial growth factors and vascular permeability","volume":"87","author":"Bates","year":"2010","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.ejca.2020.09.014_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3390\/ph12030101","article-title":"Antiviral agents in development for Zika virus infections","volume":"12","author":"Baz","year":"2019","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib17","doi-asserted-by":"crossref","first-page":"1338-1352","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"Bekerman","year":"2017","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.014_bib18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/v4061011","article-title":"Mechanisms of coronavirus cell entry mediated by the viral spike protein","volume":"4","author":"Belouzard","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.ejca.2020.09.014_bib19","first-page":"138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","author":"Bloch","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2020.09.014_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2018.07.022","article-title":"Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection","volume":"158","author":"Branche","year":"2018","journal-title":"Antivir Res"},{"issue":"17","key":"10.1016\/j.ejca.2020.09.014_bib21","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.jmb.2018.06.027","article-title":"CCR5 revisited: how mechanisms of HIV entry govern AIDS pathogenesis","volume":"430","author":"Brelot","year":"2018","journal-title":"J Mol Biol"},{"key":"10.1016\/j.ejca.2020.09.014_bib22","first-page":"134","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antivir\u00a0Res"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib23","doi-asserted-by":"crossref","first-page":"694-712","DOI":"10.1111\/j.1476-5381.2011.01279.x","article-title":"Drug targeting\u00a0of sphingolipid metabolism: sphingomyelinases and ceramidases","volume":"163","author":"Canals","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejca.2020.09.014_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","author":"Cao","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2020.09.014_bib25","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate covid-19 [published online ahead of print, 2020 jul 23]","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin Microbiol Rev"},{"issue":"10223","key":"10.1016\/j.ejca.2020.09.014_bib27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib28","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1038\/s41467-019-13086-5","article-title":"eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma","volume":"10","author":"Chan","year":"2019","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ejca.2020.09.014_bib29","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2020.09.014_bib30","doi-asserted-by":"crossref","first-page":"1289-1301","DOI":"10.1128\/JVI.01281-09","article-title":"Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB\/c mice: CD4+ T cells are important in control of SARS-CoV infection","volume":"84","author":"Chen","year":"2010","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J Med Virol"},{"issue":"11","key":"10.1016\/j.ejca.2020.09.014_bib32","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.molmed.2016.09.006","article-title":"Drug repurposing: new treatments for Zika virus infection?","volume":"22","author":"Cheng","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ejca.2020.09.014_bib33","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948950","article-title":"The dual role of c-src in cell-to-cell transmission of \u03b1-synuclein","author":"Choi","year":"2020","journal-title":"EMBO Rep"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.chembiol.2016.03.010","article-title":"GNF-2 inhibits dengue virus by targeting abl kinases and the viral E protein","volume":"23","author":"Clark","year":"2016","journal-title":"Cell Chem Biol"},{"issue":"19","key":"10.1016\/j.ejca.2020.09.014_bib36","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J Virol"},{"issue":"20","key":"10.1016\/j.ejca.2020.09.014_bib37","first-page":"30390","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"S0883-9441","author":"Cortegiani","year":"2020","journal-title":"J Crit Care"},{"key":"10.1016\/j.ejca.2020.09.014_bib38","series-title":"LiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"issue":"7","key":"10.1016\/j.ejca.2020.09.014_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102314","article-title":"Sphingosine kinase-2 maintains viral latency and survival for KSHV-infected endothelial cells","volume":"9","author":"Dai","year":"2014","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.ejca.2020.09.014_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00707-18","article-title":"Nitazoxanide inhibits human norovirus replication and synergizes with ribavirin by activation of cellular antiviral response","volume":"62","author":"Dang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ejca.2020.09.014_bib41","doi-asserted-by":"crossref","first-page":"100261","DOI":"10.1016\/j.jbo.2019.100261","article-title":"An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain","volume":"19","author":"Danson","year":"2019","journal-title":"J Bone Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2020.09.014_bib42","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1128\/JVI.00632-13","article-title":"The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase","volume":"87","author":"de Wispelaere","year":"2013","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1021\/acs.jmedchem.8b01723","article-title":"Molecular mechanism of inhibition of acid ceramidase by carmofur","volume":"62","author":"Dementiev","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2020.09.014_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2020.05.026","article-title":"Immune checkpoint inhibitors: a physiology-driven approach to the treatment of COVID-19","volume":"135","author":"Di Cosimo","year":"2020","journal-title":"Eur J Canc"},{"issue":"15","key":"10.1016\/j.ejca.2020.09.014_bib45","doi-asserted-by":"crossref","first-page":"24753","DOI":"10.18632\/oncotarget.15800","article-title":"Acid ceramidase is a novel drug target for pediatric brain tumors","volume":"8","author":"Doan","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ejca.2020.09.014_bib46","doi-asserted-by":"crossref","first-page":"4885-4893","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"18","key":"10.1016\/j.ejca.2020.09.014_bib47","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.014_bib48","first-page":"2221-2246","article-title":"Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers","volume":"7","author":"El Bairi","year":"2018","journal-title":"Canc Med"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/10408363.2017.1313190","article-title":"Prediction of\u00a0therapy response in ovarian cancer: where are we now?","volume":"54","author":"El Bairi","year":"2017","journal-title":"Crit\u00a0Rev Clin Lab Sci"},{"key":"10.1016\/j.ejca.2020.09.014_bib50","doi-asserted-by":"crossref","first-page":"2492-2498","DOI":"10.1016\/j.biopha.2018.11.097","article-title":"The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery","volume":"109","author":"El Bairi","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejca.2020.09.014_bib51","first-page":"1","article-title":"Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut [published online ahead of print, 2020 May 24]","author":"El Bairi","year":"2020","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.ejca.2020.09.014_bib52","series-title":"Covid-19: guidance on more regulatory flexibility for medicines","year":"2020"},{"key":"10.1016\/j.ejca.2020.09.014_bib53","series-title":"EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines","year":"2020"},{"issue":"7","key":"10.1016\/j.ejca.2020.09.014_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11864-020-00754-8","article-title":"Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates","volume":"21","author":"Farag","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ejca.2020.09.014_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib57","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.1038\/s41598-017-09797-8","article-title":"Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae","volume":"7","author":"Ferreira","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.09.014_bib58","article-title":"Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients:a systematic review and meta-analysis","author":"Fiolet","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"23","key":"10.1016\/j.ejca.2020.09.014_bib59","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib60","doi-asserted-by":"crossref","first-page":"L52-L58","DOI":"10.1152\/ajplung.00047.2018","article-title":"Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury","volume":"315","author":"Florence","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib61","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","article-title":"Why tocilizumab could be an effective treatment for severe COVID-19?","volume":"18","author":"Fu","year":"2020","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib62","first-page":"561-584","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Canc Metastasis Rev"},{"key":"10.1016\/j.ejca.2020.09.014_bib63","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1021\/acs.jpclett.0c01894","article-title":"Repurposing low-molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2","volume":"11","author":"Gao","year":"2020","journal-title":"J Phys Chem Lett"},{"key":"10.1016\/j.ejca.2020.09.014_bib64","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Canc Treat Rev"},{"issue":"123","key":"10.1016\/j.ejca.2020.09.014_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003500","article-title":"Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase","volume":"4","author":"Garc\u00eda","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2020.09.014_bib66","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.virusres.2019.02.011","article-title":"Drug repurposing for new, efficient, broad spectrum antivirals","volume":"264","author":"Garc\u00eda-Serradilla","year":"2019","journal-title":"Virus Res"},{"issue":"27","key":"10.1016\/j.ejca.2020.09.014_bib67","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/JCO.2014.59.5256","article-title":"Ewing sarcoma: current management and future approaches through collaboration","volume":"33","author":"Gaspar","year":"2015","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ejca.2020.09.014_bib68","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2020.09.014_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.04.009","article-title":"Complex immune dysregulation in COVID-19 patients with severe respiratory failure","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"9","key":"10.1016\/j.ejca.2020.09.014_bib71","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1358\/dot.2020.56.5.3135886","article-title":"Plitidepsin to treat multiple myeloma","volume":"56","author":"Gomes","year":"2020","journal-title":"Drugs Today"},{"issue":"7816","key":"10.1016\/j.ejca.2020.09.014_bib73","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.09.014_bib74","first-page":"104-111","article-title":"Sphingolipids and acid ceramidase as therapeutic targets in cancer therapy","volume":"138","author":"Govindarajah","year":"2019","journal-title":"Crit RevOncolHematol"},{"key":"10.1016\/j.ejca.2020.09.014_bib75","article-title":"Compassionate use of remdesivir for patients with severe covid-19 [published online ahead of print, 2020 apr 10]","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib76","first-page":"57-60","article-title":"A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies","volume":"89","author":"Gubens","year":"2015","journal-title":"Lung Canc"},{"issue":"17","key":"10.1016\/j.ejca.2020.09.014_bib77","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.ejca.2020.09.014_bib78","series-title":"Rapid repurposing of drugs for COVID-19","author":"Guy","year":"2020"},{"issue":"7","key":"10.1016\/j.ejca.2020.09.014_bib79","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib80","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","article-title":"Coronavirus puts drug repurposing on the fast track","volume":"38","author":"Harrison","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.ejca.2020.09.014_bib81","doi-asserted-by":"crossref","first-page":"133-150","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Canc"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib82","first-page":"510-520","article-title":"Targeting RNA helicases in cancer: the translation trap","volume":"1868","author":"Heerma van Voss","year":"2017","journal-title":"Biochim Biophys Acta Rev Canc"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib83","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/jcm9041225","article-title":"The COVID-19 pandemic: a comprehensive review of taxonomy, Genetics, epidemiology, diagnosis, treatment, and control","volume":"9","author":"Helmy","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib84","doi-asserted-by":"crossref","first-page":"92-101","DOI":"10.1016\/j.antiviral.2006.04.014","article-title":"Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction","volume":"74","author":"Ho","year":"2007","journal-title":"Antivir Res"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib85","doi-asserted-by":"crossref","first-page":"966-984","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2020.09.014_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2020.09.014_bib87","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/cr60292a002","article-title":"Actinomycin. Chemistry and mechanism of action","author":"Hollstein","year":"1974","journal-title":"Chem Rev"},{"key":"10.1016\/j.ejca.2020.09.014_bib88","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/duvelisib-copiktra-verastem-inc-adult-patients-relapsed-or-refractory-chronic-lymphocytic-leukemia."},{"key":"10.1016\/j.ejca.2020.09.014_bib89","unstructured":"https:\/\/www.redhillbio.com\/RedHill\/Templates\/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1365&PID=0&IID=5106Accessed 06-06-2020."},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib90","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","article-title":"Insights from nanomedicine into chloroquine efficacy against COVID-19","volume":"15","author":"Hu","year":"2020","journal-title":"Nat Nanotechnol"},{"issue":"10223","key":"10.1016\/j.ejca.2020.09.014_bib91","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.09.014_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","author":"Huang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib93","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911622","article-title":"Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress","volume":"12","author":"Humeau","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib94","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2020.09.014_bib95","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.isci.2019.07.003","article-title":"The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus","volume":"19","author":"Jasenosky","year":"2019","journal-title":"iScience"},{"issue":"19","key":"10.1016\/j.ejca.2020.09.014_bib96","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/0008-5472.CAN-19-1167","article-title":"Recent advances targeting CCR5 for cancer and its role in immuno-oncology","volume":"79","author":"Jiao","year":"2019","journal-title":"Canc Res"},{"issue":"190","key":"10.1016\/j.ejca.2020.09.014_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib98","doi-asserted-by":"crossref","first-page":"401-404","DOI":"10.1128\/jvi.29.1.401-404.1979","article-title":"Inhibition of coronavirus 229E replication by actinomycin D","volume":"29","author":"Kennedy","year":"1979","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2020.09.014_bib99","article-title":"Shape-based machine learning models for the potential novel COVID-19 protease inhibitors assisted by molecular dynamics simulation","author":"Khandelwal","year":"2020","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1128\/AAC.03659-14","article-title":"Antiviral potential of ERK\/MAPK and PI3K\/AKT\/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis","volume":"59","author":"Kindrachuk","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ejca.2020.09.014_bib101","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.amjsurg.2005.05.044","article-title":"Oral trypsin inhibitor can improve reflux esophagitis after distal gastrectomy concomitant with decreased trypsin activity","volume":"190","author":"Kono","year":"2005","journal-title":"Am J Surg"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.014_bib102","doi-asserted-by":"crossref","first-page":"L435","DOI":"10.1152\/ajplung.00234.2013","article-title":"Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS\/immune complex-induced acute lung injury","volume":"307","author":"Krupa","year":"2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"9","key":"10.1016\/j.ejca.2020.09.014_bib103","doi-asserted-by":"crossref","first-page":"2127-2143","DOI":"10.1038\/s41375-019-0517-6","article-title":"Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma","volume":"33","author":"Landgren","year":"2019","journal-title":"Leukemia"},{"issue":"Pt 12","key":"10.1016\/j.ejca.2020.09.014_bib104","first-page":"3285-3288","article-title":"Differential in\u00a0vitro inhibition of feline enteric coronavirus and feline infectious peritonitis virus by actinomycin D","volume":"73","author":"Lewis","year":"1992","journal-title":"J Gen Virol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib105","doi-asserted-by":"crossref","first-page":"247-253","DOI":"10.1016\/j.ygyno.2017.11.031","article-title":"The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: a network meta-analysis","volume":"148","author":"Li","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2020.09.014_bib106","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19 [published online ahead of print, 2020 Mar 5]","author":"Li","year":"2020","journal-title":"J Pharm Anal"},{"key":"10.1016\/j.ejca.2020.09.014_bib107","article-title":"HCFU inhibits cervical cancer cells growth and metastasis by inactivating Wnt\/\u03b2-catenin pathway","author":"Liu","year":"2017","journal-title":"J Cell Biochem"},{"issue":"12","key":"10.1016\/j.ejca.2020.09.014_bib108","doi-asserted-by":"crossref","first-page":"1449-1458","DOI":"10.1517\/14728220903357512","article-title":"Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy","volume":"13","author":"Liu","year":"2009","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"10.1016\/j.ejca.2020.09.014_bib109","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis","volume":"4","author":"Lucas","year":"2014","journal-title":"Canc Discov"},{"issue":"8","key":"10.1016\/j.ejca.2020.09.014_bib110","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2020.09.014_bib111","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/2159-8290.CD-20-0596","article-title":"Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers","volume":"10","author":"Luo","year":"2020","journal-title":"Canc Discov"},{"issue":"3","key":"10.1016\/j.ejca.2020.09.014_bib112","doi-asserted-by":"crossref","first-page":"950-956","DOI":"10.1016\/j.athoracsur.2017.10.002","article-title":"Imatinib is protective against ischemia-reperfusion injury in an ex\u00a0vivo rabbit model of lung injury","volume":"105","author":"Magruder","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ejca.2020.09.014_bib113","article-title":"Toremifene versus tamoxifen for advanced breast cancer","volume":"7","author":"Mao","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.ejca.2020.09.014_bib114","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib115","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"10.1016\/j.ejca.2020.09.014_bib116","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdu363","article-title":"A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer","volume":"25","author":"McNeish","year":"2014","journal-title":"Ann Oncol"},{"issue":"10229","key":"10.1016\/j.ejca.2020.09.014_bib117","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejca.2020.09.014_bib118","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug repurposing for viral infectious diseases: how far are we?","volume":"26","author":"Mercorelli","year":"2018","journal-title":"Trends Microbiol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib119","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.devcel.2015.03.002","article-title":"CALM regulates clathrin-coated vesicle size and maturation by directly sensing and driving membrane curvature","volume":"33","author":"Miller","year":"2015","journal-title":"Dev Cell"},{"key":"10.1016\/j.ejca.2020.09.014_bib120","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3389\/fmicb.2017.01129","article-title":"Abl tyrosine kinase regulates hepatitis C virus entry","volume":"8","author":"Min","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ejca.2020.09.014_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib122","first-page":"77-83","article-title":"Postoperative adjuvant use of carmofur for early breast cancer","volume":"49","author":"Morimoto","year":"2003","journal-title":"Osaka City Med J"},{"issue":"4 suppl","key":"10.1016\/j.ejca.2020.09.014_bib123","first-page":"533","article-title":"Antiproteases in the treatment of chronic pancreatitis","volume":"8","author":"Motoo","year":"2007","journal-title":"JOP"},{"key":"10.1016\/j.ejca.2020.09.014_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30282-4","article-title":"Tocilizumab for severe COVID-19 pneumonia","author":"Mourad","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"21","key":"10.1016\/j.ejca.2020.09.014_bib125","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121951","article-title":"eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer","volume":"4","author":"M\u00fcller","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib126","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3390\/md11051677","article-title":"c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity","volume":"11","author":"Mu\u00f1oz-Alonso","year":"2013","journal-title":"Mar Drugs"},{"key":"10.1016\/j.ejca.2020.09.014_bib127","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0958-y","article-title":"Targeting nuclear import and export in hematological malignancies","author":"Nachmias","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ejca.2020.09.014_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002845","article-title":"Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly","volume":"8","author":"Neveu","year":"2012","journal-title":"PLoS Pathog"},{"issue":"8","key":"10.1016\/j.ejca.2020.09.014_bib129","doi-asserted-by":"crossref","first-page":"4387-4404","DOI":"10.1128\/JVI.02705-14","article-title":"AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets","volume":"89","author":"Neveu","year":"2015","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/pharmaceutics10020045","article-title":"Molecular targeting of acid ceramidase in glioblastoma: a review of its role, potential treatment, and challenges","volume":"10","author":"Nguyen","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejca.2020.09.014_bib131","doi-asserted-by":"crossref","first-page":"52-61","DOI":"10.1016\/j.lfs.2016.05.036","article-title":"Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis","volume":"157","author":"Patel","year":"2016","journal-title":"Life Sci"},{"issue":"11","key":"10.1016\/j.ejca.2020.09.014_bib132","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/ijms18112413","article-title":"Targeting immune cell checkpoints during sepsis","volume":"18","author":"Patil","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2020.09.014_bib133","series-title":"Disruption of the CCL5\/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19","author":"Patterson","year":"2020"},{"key":"10.1016\/j.ejca.2020.09.014_bib134","article-title":"Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial","author":"Perrone","year":"2020","journal-title":"medRxiv"},{"issue":"3","key":"10.1016\/j.ejca.2020.09.014_bib135","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/(SICI)1099-1573(200005)14:3<187::AID-PTR572>3.0.CO;2-I","article-title":"Antiproliferative effects of compounds derived from plants of Northeast Brazil","volume":"14","author":"Pessoa","year":"2000","journal-title":"Phytother Res"},{"key":"10.1016\/j.ejca.2020.09.014_bib136","article-title":"PharmaMar has submitted a Phase II clinical trial of Aplidin\u00ae (plitidepsin) for the treatment of COVID-19 to the Spanish Medicines Agency","year":"2020","journal-title":"PharmaMar"},{"key":"10.1016\/j.ejca.2020.09.014_bib137","article-title":"PharmaMar reports positive results for Aplidin\u00ae against coronavirus HCoV-229E","year":"2020","journal-title":"PharmaMar"},{"key":"10.1016\/j.ejca.2020.09.014_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30161-2","article-title":"Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations","author":"Phua","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ejca.2020.09.014_bib139","doi-asserted-by":"crossref","first-page":"1349-1363","DOI":"10.1016\/j.cellsig.2016.06.007","article-title":"Recent advances in the development of sphingosine kinase inhibitors","volume":"28","author":"Pitman","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.ejca.2020.09.014_bib140","doi-asserted-by":"crossref","first-page":"67-75","DOI":"10.1016\/j.antiviral.2018.05.001","article-title":"Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment","volume":"155","author":"Pu","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.ejca.2020.09.014_bib141","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.2904","article-title":"Characteristics and strength of evidence of COVID-19 studies registered on ClinicalTrials.gov","author":"Pundi","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib142","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.ejca.2020.09.014_bib143","doi-asserted-by":"crossref","first-page":"581-591","DOI":"10.1016\/j.tips.2017.04.003","article-title":"Sphingosine kinase 2 in autoimmune\/inflammatory disease and the development of sphingosine kinase 2 inhibitors","volume":"38","author":"Pyne","year":"2017","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"10.1016\/j.ejca.2020.09.014_bib144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076469","article-title":"Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation","volume":"8","author":"Qian","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2020.09.014_bib145","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib146","doi-asserted-by":"crossref","first-page":"571-580","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.09.014_bib147","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3389\/fimmu.2019.02298","article-title":"The diverse function of PD-1\/PD-L pathway beyond cancer","volume":"10","author":"Qin","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2020.09.014_bib148","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/srep01035","article-title":"Discovery of highly potent acid ceramidase inhibitors with in\u00a0vitro tumor chemosensitizing activity","volume":"3","author":"Realini","year":"2013","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ejca.2020.09.014_bib149","first-page":"e61","article-title":"Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex","volume":"4","author":"Reid","year":"2015","journal-title":"Emerg Microb Infect"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib150","doi-asserted-by":"crossref","first-page":"143-155","DOI":"10.1515\/bmc-2014-0003","article-title":"Endocytosis and the Src family of non-receptor tyrosine kinases","volume":"5","author":"Reinecke","year":"2014","journal-title":"Biomol Concepts"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib151","doi-asserted-by":"crossref","first-page":"264-279","DOI":"10.1002\/mc.20665","article-title":"Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis","volume":"50","author":"Rho","year":"2011","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.ejca.2020.09.014_bib152","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720930629","article-title":"Selinexor in relapsed\/refractory multiple myeloma","volume":"11","author":"Richter","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.ejca.2020.09.014_bib153","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","author":"Riva","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ejca.2020.09.014_bib154","doi-asserted-by":"crossref","first-page":"L1294","DOI":"10.1152\/ajplung.00031.2015","article-title":"Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury","volume":"309","author":"Rizzo","year":"2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib155","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/09553000903264531","article-title":"Aplidin as a potential adjunct to radiation therapy: in\u00a0vitro studies","volume":"86","author":"Rockwell","year":"2010","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.ejca.2020.09.014_bib156","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ejca.2020.09.014_bib157","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir Res"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib158","doi-asserted-by":"crossref","first-page":"271-285","DOI":"10.1038\/nrc.2017.13","article-title":"Microbiota: a key orchestrator of cancer therapy","volume":"17","author":"Roy","year":"2017","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2020.09.014_bib159","first-page":"1","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","author":"Ruan","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ejca.2020.09.014_bib160","article-title":"The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication","volume":"7","author":"Sacramento","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.09.014_bib161","first-page":"1","article-title":"Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy","author":"Saini","year":"2020","journal-title":"Br J Canc"},{"issue":"9","key":"10.1016\/j.ejca.2020.09.014_bib162","doi-asserted-by":"crossref","first-page":"536-544","DOI":"10.1093\/jjco\/hyi147","article-title":"An individual patient data meta-analysis of adjuvant therapy with carmofur in patients with curatively resected colon cancer","volume":"35","author":"Sakamoto","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.09.014_bib163","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","article-title":"The PD-1\/PD-L1 axis and virus infections: a delicate balance","volume":"9","author":"Sch\u00f6nrichG","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib164","doi-asserted-by":"crossref","first-page":"63-69","DOI":"10.1089\/dna.2017.4033","article-title":"Repurposing of kinase inhibitors as broad-spectrum antiviral drugs","volume":"37","author":"Schor","year":"2018","journal-title":"DNA Cell Biol"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib165","doi-asserted-by":"crossref","first-page":"64-69","DOI":"10.1016\/j.antiviral.2011.02.008","article-title":"Emodin inhibits current through SARS-associated coronavirus 3a protein","volume":"90","author":"Schwarz","year":"2011","journal-title":"Antivir Res"},{"key":"10.1016\/j.ejca.2020.09.014_bib166","article-title":"Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy","author":"Shah","year":"2019","journal-title":"Canc Immun"},{"key":"10.1016\/j.ejca.2020.09.014_bib167","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","author":"Shang","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ejca.2020.09.014_bib168","doi-asserted-by":"crossref","first-page":"1379-1387","DOI":"10.1586\/14737140.2015.1115350","article-title":"Valrubicin in refractory non-muscle invasive bladder cancer","volume":"15","author":"Sharma","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2020.09.014_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2017.07.016","article-title":"TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections","volume":"142","author":"Shen","year":"2017","journal-title":"Biochimie"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.014_bib170","doi-asserted-by":"crossref","first-page":"601-607","DOI":"10.1111\/ejh.12877","article-title":"Carfilzomib-containing combinations as frontline therapy for multiple myeloma: a meta-analysis of 13 trials","volume":"98","author":"Sheng","year":"2017","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.014_bib171","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3390\/v10060283","article-title":"Saracatinib inhibits Middle East respiratory syndrome-coronavirus replication in\u00a0vitro","volume":"10","author":"Shin","year":"2018","journal-title":"Viruses"},{"issue":"23","key":"10.1016\/j.ejca.2020.09.014_bib172","doi-asserted-by":"crossref","first-page":"12552","DOI":"10.1128\/JVI.01890-13","article-title":"Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2","volume":"87","author":"Shirato","year":"2013","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib173","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib174","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib175","doi-asserted-by":"crossref","first-page":"619-630","DOI":"10.1099\/jgv.0.001047","article-title":"Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors","volume":"99","author":"Sisk","year":"2018","journal-title":"J Gen Virol"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib176","first-page":"433-445","article-title":"Regulation and function of sphingosine kinase 2 in diseases","volume":"33","author":"Song","year":"2018","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.ejca.2020.09.014_bib177","doi-asserted-by":"crossref","first-page":"4437-4449","DOI":"10.2147\/OTT.S208519","article-title":"Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in\u00a0vitro and in\u00a0vivo","volume":"12","author":"Song","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"24","key":"10.1016\/j.ejca.2020.09.014_bib178","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.09.014_bib179","article-title":"Treatment of patients with relapsed or refractory mantle cell lymphoma with zanubrutinib, a selective inhibitor of bruton's tyrosine kinase","author":"Song","year":"2020","journal-title":"Clin Canc Res"},{"issue":"9","key":"10.1016\/j.ejca.2020.09.014_bib180","doi-asserted-by":"crossref","first-page":"2139-2150","DOI":"10.1007\/s00277-019-03739-2","article-title":"Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed\/refractory multiple myeloma","volume":"98","author":"Spicka","year":"2019","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib181","doi-asserted-by":"crossref","first-page":"400-402","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.ejca.2020.09.014_bib182","article-title":"The tyrosine kinase inhibitor imatinib prevents lung injury and death after intravenous LPS in mice","volume":"3","author":"Stephens","year":"2015","journal-title":"Phys Rep"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib183","doi-asserted-by":"crossref","first-page":"142-152","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.014_bib184","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S1470-2045(19)30271-2","article-title":"Master protocols in clinical trials: a universal Swiss Army knife?","volume":"20","author":"Sudhop","year":"2019","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2020.09.014_bib185","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","article-title":"Selinexor: first global approval","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib186","doi-asserted-by":"crossref","first-page":"91-97","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib187","doi-asserted-by":"crossref","first-page":"1717-1724","DOI":"10.1016\/j.athoracsur.2016.05.037","article-title":"Protective effects of imatinib on ischemia\/reperfusion injury in rat lung","volume":"102","author":"Tanaka","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ejca.2020.09.014_bib188","article-title":"Investigation of N Terminal domain of SARS CoV 2 nucleocapsid protein with antiviral compounds based on molecular modeling approach","author":"Tatar","year":"2020","journal-title":"Sci Open Preprint"},{"issue":"4","key":"10.1016\/j.ejca.2020.09.014_bib189","doi-asserted-by":"crossref","first-page":"346-353","DOI":"10.1097\/COH.0000000000000479","article-title":"The return of PRO 140, a CCR5-directed mAb","volume":"13","author":"Thompson","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2020.09.014_bib190","first-page":"1530","article-title":"Preclinical evaluation of eFT226, a novel, potent and selective eIF4A inhibitor with anti-tumor activity in B-cell malignancies","volume":"130","author":"Thompson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.09.014_bib191","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2017.10.002","article-title":"The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide","volume":"147","author":"Tilmanis","year":"2017","journal-title":"Antivir Res"},{"key":"10.1016\/j.ejca.2020.09.014_bib192","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fmed.2020.00367","article-title":"Semantic and geographical analysis of COVID-19 trials reveals a fragmented clinical research landscape likely to impair informativeness","volume":"7","author":"Tini","year":"2020","journal-title":"Front Med"},{"issue":"21","key":"10.1016\/j.ejca.2020.09.014_bib193","doi-asserted-by":"crossref","first-page":"1912-1915","DOI":"10.1182\/blood.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.09.014_bib194","article-title":"Exportin 1 inhibition as antiviral therapy [published online ahead of print, 2020 Jun 20]","author":"Uddin","year":"2020","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.014_bib195","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00473-12","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","volume":"3","author":"van Boheemen","year":"2012","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.ejca.2020.09.014_bib196","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrurol.2017.163","article-title":"Position paper: rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol","volume":"14","author":"van den Heuvel-Eibrink","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib197","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000054","article-title":"SARS-coronavirus replication\/transcription complexes are membrane-protected and need a host factor for activity in\u00a0vitro","volume":"4","author":"van Hemert","year":"2008","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.ejca.2020.09.014_bib198","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.09.014_bib199","doi-asserted-by":"crossref","first-page":"100634","DOI":"10.1016\/j.blre.2019.100634","article-title":"JAKs to STATs: a tantalizing therapeutic target in acute myeloid leukemia","volume":"40","author":"Venugopal","year":"2020","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.ejca.2020.09.014_bib200","doi-asserted-by":"crossref","first-page":"799-807","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib201","first-page":"1-9","article-title":"Toremifene for breast cancer: a review of 20 years of data","volume":"14","author":"Vogel","year":"2014","journal-title":"Clin Breast Canc"},{"issue":"9","key":"10.1016\/j.ejca.2020.09.014_bib202","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","article-title":"Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma","volume":"36","author":"Vogl","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.09.014_bib203","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3181\/00379727-45-11768","article-title":"Bacteriostatic and bactericidal substances produced by a soil actinomyces","volume":"45","author":"Waksman","year":"1940","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.ejca.2020.09.014_bib204","first-page":"1-18","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2020.09.014_bib206","article-title":"Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study [published online ahead of print, 2020 may 4]","author":"Wang","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.ejca.2020.09.014_bib207","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","author":"Wang","year":"2020","journal-title":"Cell"},{"issue":"7058","key":"10.1016\/j.ejca.2020.09.014_bib208","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature03987","article-title":"Pathophysiological consequences of VEGF-induced vascular permeability","volume":"437","author":"Weis","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib209","doi-asserted-by":"crossref","first-page":"13738","DOI":"10.1038\/s41598-017-14221-2","article-title":"A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery","volume":"7","author":"Wolfram","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2020.09.014_bib210","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.ejca.2020.09.014_bib211","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.bbrc.2018.07.112","article-title":"KPT-330, a potent and selective CRM1 inhibitor, exhibits anti-inflammation effects and protection against sepsis","volume":"503","author":"Wu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.ejca.2020.09.014_bib212","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J Immunother Canc"},{"issue":"10","key":"10.1016\/j.ejca.2020.09.014_bib213","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"Xu","year":"2016","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib214","doi-asserted-by":"crossref","first-page":"299-307","DOI":"10.1007\/s00277-017-3173-9","article-title":"Pooled analysis of the reports of carfilzomib\/ixazomib combinations for relapsed\/refractory multiple myeloma","volume":"97","author":"Xu","year":"2018","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.ejca.2020.09.014_bib215","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.7150\/ijbs.45498","article-title":"Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19","volume":"16","author":"Yang","year":"2020","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.ejca.2020.09.014_bib216","doi-asserted-by":"crossref","first-page":"102434","DOI":"10.1016\/j.jaut.2020.102434","article-title":"The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China","volume":"109","author":"Yang","year":"2020","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ejca.2020.09.014_bib217","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25729","article-title":"A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option","author":"Yao","year":"2020","journal-title":"J Med Virol"},{"issue":"3","key":"10.1016\/j.ejca.2020.09.014_bib218","doi-asserted-by":"crossref","first-page":"232-240","DOI":"10.1177\/1091581820918511","article-title":"Nonclinical safety assessment of zanubrutinib: a novel irreversible BTK inhibitor","volume":"39","author":"Zhang","year":"2020","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.ejca.2020.09.014_bib219","first-page":"1969474","article-title":"Programmed cell death-1\/programmed death-ligand 1 blockade improves survival of animals with sepsis: a systematic review and meta-analysis","volume":"2018","author":"Zhang","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ejca.2020.09.014_bib220","article-title":"Viral and host factors related to the clinical outcome of COVID-19","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.09.014_bib221","doi-asserted-by":"crossref","first-page":"105982","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies","author":"Zhao","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"7610","key":"10.1016\/j.ejca.2020.09.014_bib222","doi-asserted-by":"crossref","first-page":"169-172","DOI":"10.1038\/nature18615","article-title":"Toremifene interacts with and destabilizes the Ebola virus glycoprotein","volume":"535","author":"Zhao","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.09.014_bib223","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2020.09.014_bib224","doi-asserted-by":"crossref","first-page":"1265-1275","DOI":"10.1007\/s12013-014-0050-1","article-title":"Knockdown of Burton's tyrosine kinase confers potent protection against sepsis-induced acute lung injury","volume":"70","author":"Zhou","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.ejca.2020.09.014_bib225","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Zhou","year":"2020","journal-title":"Cell Discov"},{"issue":"8","key":"10.1016\/j.ejca.2020.09.014_bib226","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejca.2020.09.014_bib227","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1080\/14656566.2017.1404575","article-title":"An overview of the role of carfilzomib in the treatment of multiple myeloma","volume":"18","author":"Ziogas","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.ejca.2020.09.014_bib228","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5114\/aoms.2020.94504","article-title":"Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2","volume":"16","author":"Nabavi","year":"2020","journal-title":"Arch Med Sci"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920305207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920305207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:39Z","timestamp":1760732979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920305207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":227,"alternative-id":["S0959804920305207"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.09.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing anticancer drugs for the management of COVID-19","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}